Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Karia  PS, Han  J, Schmults  CD.  Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012.  J Am Acad Dermatol. 2013;68(6):957-966.PubMedGoogle ScholarCrossref
Chang  AL, Kim  J, Luciano  R, Sullivan-Chang  L, Colevas  AD.  A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor.  JAMA Dermatol. 2016;152(1):106-108.PubMedGoogle ScholarCrossref
Borradori  L, Sutton  B, Shayesteh  P, Daniels  GA.  Rescue therapy with anti-programmed cell death protein 1 inhibitors (PD-1) of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in 5 cases [published online April 5, 2016].  Br J Dermatol. doi:10.1111/bjd.14642PubMedGoogle Scholar
Jarkowski  A  III, Hare  R, Loud  P,  et al.  Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a review of the literature [published online May 29, 2014].  Am J Clin Oncol. doi:10.1097/COC.0000000000000088PubMedGoogle Scholar
Wu  JJ, Orengo  IF.  Squamous cell carcinoma in solid-organ transplantation.  Dermatol Online J. 2002;8(2):4.PubMedGoogle Scholar
Research Letter
January 2017

Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma

Author Affiliations
  • 1Department of Dermatology, Stanford University School of Medicine, Redwood City, California
  • 2Department of Medicine–Head and Neck Oncology, Stanford University School of Medicine, Stanford, California
JAMA Dermatol. 2017;153(1):92-94. doi:10.1001/jamadermatol.2016.3884

Cutaneous squamous cell carcinoma (CSCC) is one of the 2 most common types of human malignant tumors.1 Although most CSCCs are effectively treated with excision, recurrent disease near vital structures or metastasis can be challenging to treat. Currently, there is no accepted standard of care for unresectable or metastatic CSCCs, although platinum compounds, taxanes, and fluorouracil are commonly used. Recently, 2 reports of CSCC cases treated with programmed cell death 1 (PD-1) inhibitors have been published but contain limited follow-up times (<7 months).2,3 The safety profile of PD-1 inhibitors in CSCCs is also not well known. We present 6 consecutive cases of advanced CSCCs treated with PD-1 inhibitors, including an extended follow-up of 1 previously reported index case2 to 21 months of progression-free survival (PFS).